Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells
Cancer Immunology, Immunotherapy · 2023
DOI: 10.1007/s00262-023-03486-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2023. Verfasst von Marion Grard und 14 weiteren Autor:innen. Beteiligte Einrichtung: Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, F-44000, Nantes, France. Hauptthemen laut MEDLINE: Oncolytic Viruses, Melanoma, Measles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: La Ligue Régionale Grand Ouest contre le Cancer, association ARSMESO44, Fondation ARC.
Abstract (Originalsprache)
Antitumor virotherapy stimulates the antitumor immune response during tumor cell lysis induced by oncolytic viruses (OVs). OV can be modified to express additional transgenes that enhance their therapeutic potential. In this study, we armed the spontaneously oncolytic Schwarz strain of measles viruses (MVs) with the gene encoding the cancer/testis antigen NY-ESO-1 to obtain MVny. We compared MV and MVny oncolytic activity and ability to induce NY-ESO-1 expression in six human melanoma cell lines. After MVny infection, we measured the capacity of melanoma cells to present NY-ESO-1 peptides to CD4 + and CD8 + T cell clones specific for this antigen. We assessed the ability of MVny to induce NY-ESO-1 expression and presentation in monocyte-derived dendritic cells (DCs). Our results show that MVny and MV oncolytic activity are similar with a faster cell lysis induced by MVny. We also observed that melanoma cell lines and DC expressed the NY-ESO-1 protein after MVny infection. In addition, MVny-infected melanoma cells and DCs were able to stimulate NY-ESO-1-specific CD4 + and CD8 + T cells. Finally, MVny was able to induce DC maturation. Altogether, these results show that MVny could be an interesting candidate to stimulate NY-ESO-1-specific T cells in melanoma patients with NY-ESO-1-expressing tumor cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, F-44000, Nantes, France.
- Labex IGO, Immunology Graft Oncology, Nantes, France.
- Vaccines Innovation Laboratory, Institut Pasteur, Université de Paris Cité, 75015, Paris, France.
- Nantes Université, Université d'Angers, Inserm, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, 44000, Nantes, France.
- Oncovita, 75015, Paris, France.
- Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, F-44000, Nantes, France. jean-francois.fonteneau@inserm.fr.
Förderung
- La Ligue Régionale Grand Ouest contre le Cancer
- association ARSMESO44
- Fondation ARC
- Agence Nationale de la Recherche
- Agence Nationale pour la Recherche, France
Zitieren
APA
Grard, M., Idjellidaine, M., Arbabian, A., Chatelain, C., Berland, L., Combredet, C., Dutoit, S., Deshayes, S., Dehame, V., Labarrière, N., Fradin, D., Boisgerault, N., Blanquart, C., Tangy, F., & Fonteneau, J. F. (2023). Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-023-03486-4
Vancouver
Grard M, Idjellidaine M, Arbabian A, Chatelain C, Berland L, Combredet C, et al. Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells. Cancer Immunology, Immunotherapy. 2023. doi:10.1007/s00262-023-03486-4
BibTeX
@article{Grard2023,
author = {Grard, Marion and Idjellidaine, Mohamed and Arbabian, Atousa and Chatelain, Camille and Berland, Laurine and Combredet, Chantal and Dutoit, Soizic and Deshayes, Sophie and Dehame, Virginie and Labarrière, Nathalie and Fradin, Delphine and Boisgerault, Nicolas and Blanquart, Christophe and Tangy, Frédéric and Fonteneau, Jean-François},
title = {Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells},
journal = {Cancer Immunology, Immunotherapy},
year = {2023},
doi = {10.1007/s00262-023-03486-4}
}
EUVIMED